A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Condition:   Melanoma Stage III Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib Sponsors:   Melanoma Institute Australia;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials